Summary
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, is anticipated to prolong survival with inhibition of angiogenesis in patients with non-small-cell lung cancer. Rare life-threatening adverse events affecting the digestive tract have been reported, such as gastrointestinal hemorrhage and bowel perforation. A 62-year-old Japanese woman who was diagnosed as having stage IIIB (cT4N2M0) lung adenocarcinoma received chemotherapy with bevacizumab, pemetrexed and carboplatin every 3 weeks for four cycles, which resulted in a partial response, and then continued with maintenance bevacizumab monotherapy. Fourteen days after completion of the seventh cycle of bevacizumab maintenance therapy, the patient developed sudden abdominal pain with more than 10 episodes of hematochezia per day. On the basis of colonoscopic and pathological findings, ulcerative colitis (UC) with severe pancolitis was diagnosed. This case was unresponsive to medical treatment and required subtotal colectomy for management of the ulcerative colitis. This is the first reported case of ulcerative colitis occurring during bevacizumab therapy. The anti-angiogenesis activity of bevacizumab may have been involved in the development and exacerbation of UC in this patient.
Similar content being viewed by others
References
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568
Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J et al (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733–740
Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S (2015) Efficacy of oxaliplatin-based chemotherapy+bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol 38:227–233
Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G (2007) Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2:571–573
Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U (2009) Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Investig New Drugs 27:184–187
Kornbluth A, Sachar DB (2004) Ulcerative colitis practice guideline in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gasteroenterol 99:1371–1385
Delco F, Sonnenberg A (1999) Exposure to risk factors for ulcerative colitis occurs during an early period of life. Am J Gastroenterol 94:679–684
Nakamura Y, Kobayashi M, Nagai M, Iwata H, Nose T, Yamamoto M et al (1994) A case–control study of ulcerative colitis in Japan. J Clin Gastroenterol 18:72–79
Freeman HJ (2012) Colitis associated with biological agents. World J Gastroenterol 18:1871–1874
Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F (2008) Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 19:1975
Acknowledgments
There was no funding source to acknowledge.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanaka, M., Ishii, H., Azuma, K. et al. Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab. Invest New Drugs 33, 1133–1135 (2015). https://doi.org/10.1007/s10637-015-0279-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-015-0279-6